Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Merck & Co. patents new inhibitors of Mdm2-p53 interaction

May 11, 2011

Bayer's regorafenib receives FDA fast track status in GIST

May 10, 2011

Wilex completes patient recruitment in phase II Mesupron trial

May 10, 2011

Astellas and Medivation begin new phase II MDV-3100 trial in prostate cancer

May 10, 2011

New ALK tyrosine kinase receptor inhibitors presented

May 10, 2011

Favorable preclinical data disclosed on HSP 90 inhibitor MPC-3100

May 10, 2011

Merrimack regains rights to nanoliposomal irinotecan from PharmaEngine

May 10, 2011

Novel CRAC inhibitors presented

May 10, 2011

TGen licenses selective histone deacetylase inhibitors to Oncoholdings

May 9, 2011

Chugai seeks approval for new indications of Herceptin in Japan

May 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...